login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Study says that there is no evidence to support concerns that neurodegenerative disease-associated proteins transmit Alzheimer’s or Parkinson’s disease


Tuesday, 12 Feb 2013 11:46
Pathological deposits of Alzheimer's disease and Parkinson's disease-associated proteins
Pathological deposits of Alzheimer's disease and Parkinson's disease-associated proteins

On 4 February 2013, in a study published online in JAMA Neurology, by David Irwin, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA, and colleagues, reported a first group of recipients of cadaver-derived human growth hormone (c-hGH) who do not appear to be at increased risk for Alzheimer and Parkinson disease despite their likely exposure to neurodegenerative disease-associated proteins and elevated risk of infectious prion protein-related disease.


Irwin et al looked for evidence for human-to-human transmission of Alzheimer disease, Parkinson disease, and related neurodegenerative disease-associated proteins in c-hGH recipients. (Image: A=AB, the main component of Alzheimer’s disease-associated plaques, B=Tau, the main component of Alzheimer’s disease-associated tangles, C=Alpha-synuclein, the main component of Lewy bodies in Parkinson’s disease).

The study included 34 routine autopsy patients and a group of c-hGH recipients in the National Hormone and Pituitary Program (NHPP). No cases of Alzheimer’s disease or Parkinson’s disease were identified, according to the study results.

“We found no evidence to support concerns that neurodegenerative disease-associated proteins underlying Alzheimer’s disease and Parkinson’s disease transmit disease in humans despite evidence of their cell-to-cell transmission in model systems of these disorders. Further monitoring is required to confirm these conclusions,” the authors added.




Add New Comment

Related Items


Most popular


MR CLEAN: Better outcomes with intervention in ischaemic stroke patients
Thursday, 18 Dec 2014
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in ... MR CLEAN: Better outcomes with intervention in ischaemic stroke patients

Philips launches DoseWise Portal radiation dose management software
Monday, 01 Dec 2014
Royal Philips has introduced the DoseWise Portal, a comprehensive radiation dose management software solution aimed at managing radiation exposure risk to patients and their caregivers. Philips launches DoseWise Portal radiation dose management software

PulseRider safe and effective in early USA experience
Thursday, 08 Jan 2015
Initial experience with PulseRider (Pulsar Vascular) has shown the device to be safe and effective as an adjunct in the treatment of bifurcation aneurysms arising at the basilar apex or carotid ... PulseRider safe and effective in early USA experience

Features


TeleStroke Units improve stroke care in underserved areas
Wednesday, 07 Jan 2015
Peter Müller-Barna writes that the use of telemedicine to ensure 24/7 access to consultation and care in rural areas is one of the major recommendations of the American Stroke Association in their ... TeleStroke Units improve stroke care in underserved areas

Impact“ful” moments
Friday, 05 Dec 2014
Once a year, in almost ritualised fashion, the editors of peer-reviewed journals anxiously await publication of the Thomson Reuters Impact Factor. Journals in the “neuro” space are no exception to ... Impact“ful” moments

Profiles


Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions